|  | |
| Clinical data | |
|---|---|
| Trade names | Navane | 
| AHFS/Drugs.com | Monograph | 
| MedlinePlus | a682867 | 
| Routes of administration | Oral | 
| ATC code | |
| Legal status | |
| Legal status | 
 | 
| Pharmacokinetic data | |
| Metabolism | Hepatic | 
| Biological half-life | 10-20 hours | 
| Identifiers | |
| 
 | |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| ECHA InfoCard | 100.024.547 | 
| Chemical and physical data | |
| Formula | C23H29N3O2S2 | 
| Molar mass | 443.627 g/mol | 
| 3D model (Jmol) | |
| 
 | |
| 
 | |
Tiotixene (INN) or Thiothixene (USAN; Navane) is a typical antipsychotic drug of the thioxanthene class used in the treatment of psychoses like schizophrenia. It was introduced on July 24, 1967 by Pfizer.